Skip to content
A738Assembly2023-2024 SessionSame asS927

Cover Genetic Cancer Screening

Official title

“Requires health insurance policies to cover comprehensive genetic screening for ovarian and prostate cancers”

Sponsor Nily RozicAD-25+7 co-sponsorsAffects Finance
Status
Stricken
Impact
8/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

The bill requires health insurance policies in New York to fully cover comprehensive genetic and FDA-approved biomarker testing for ovarian and prostate cancers, with no cost to patients or their families.

Why it matters

  1. Enables earlier and more personalized treatment. By ensuring full coverage for comprehensive genetic and biomarker testing both before and after diagnosis, the bill allows patients and their doctors to make more informed, targeted treatment decisions, potentially improving outcomes and survival rates for ovarian and prostate cancers.

  2. Extends support to families and addresses inherited risk. The law requires insurance to cover genetic testing for not just patients but also their family members, helping at-risk relatives understand their cancer risk and take preventive actions or undergo early screening.

  3. Protects against genetic discrimination. The bill explicitly prohibits insurers from using genetic test results against family members for coverage decisions, addressing concerns about genetic discrimination and promoting more people to seek testing without fear of insurance repercussions.

  4. Removes financial barriers to essential testing. By mandating that insurers cover all associated costs without deductibles or coinsurance, the legislation eliminates out-of-pocket expenses, ensuring that financial constraints do not prevent access to potentially life-saving diagnostics.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Cover Genetic Cancer Screening

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Nily Rozic

Assembly Member · Assembly District 25

Chair, Consumer Affairs and Protection

History

  1. Enacting clause stricken
  2. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S927Senate

Cover Genetic Cancer Screening

In Senate Committee · Insurance · Sponsor Roxanne J. Persaud

Impact 8 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

738

2023-2024 Regular Sessions

IN ASSEMBLY

January 11, 2023

Introduced by M. of A. ROZIC, AUBRY, BRONSON, COLTON, COOK, OTIS, SIMON, WEPRIN -- Multi-Sponsored by -- M. of A. GUNTHER, RIVERA -- read once and referred to the Committee on Insurance

AN ACT to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "Ana Lucia act".

§ 2. Paragraph 11-a of subsection (i) of section 3216 of the insurance law is amended by adding a new subparagraph (C) to read as follows:

(C) (i) Such policy shall provide additional full coverage for comprehensive genetic testing and FDA approved testing based on family or person's history for prostatic and ovarian cancer when recommended by a doctor, a board-certified geneticist or a board-certified genetic counselor. Such coverage shall also be provided after the patient's initial diagnosis. Patients need to know if they carry the genetic or inheritance mutation, which can help to determine possible treatments. Genetic screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family members that carry the genetic or inheritance mutation for insurance coverage purposes.

(ii) All costs associated with such additional full coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 3. Paragraph 11-a of subsection (l) of section 3221 of the insurance law is amended by adding a new subparagraph (C) to read as follows:

(C)(i) Such policy shall provide additional full coverage for comprehensive genetic testing and FDA approved testing based on family or person's history for prostatic and ovarian cancer when recommended by a

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00460-01-3

doctor, a board-certified geneticist or a board-certified genetic counselor. Such coverage shall also be provided after the patient's initial diagnosis. Patients need to know if they carry the genetic or inheritance mutation, which can help to determine possible treatments. Genetic screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family members that carry the genetic or inheritance mutation for insurance coverage purposes.

(ii) All costs associated with such additional full coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 4. Subsection (z-1) of section 4303 of the insurance law is amended by adding a new paragraph 3 to read as follows:

(3)(A) Such policy shall provide additional full coverage for comprehensive genetic testing and FDA approved testing based on family or person's history for prostatic and ovarian cancer when recommended by a doctor, a board-certified geneticist or a board-certified genetic counselor.

(B) All costs associated with such additional full coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer. Such coverage shall also be provided after the patient's initial diagnosis. Patients need to know if they carry the genetic or inheritance mutation, which can help to determine possible treatments. Genetic screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family members that carry the genetic or inheritance mutation for insurance coverage purposes.

§ 5. This act shall take effect on the sixtieth day after it shall have become a law and shall apply to all policies, contracts and certificates issued, renewed, modified, altered or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.